Your browser doesn't support javascript.
loading
The Scleroderma Patient-Centered Intervention Network Self-Management Program: Protocol for a Randomized Feasibility Trial.
Carrier, Marie-Eve; Kwakkenbos, Linda; Nielson, Warren R; Fedoruk, Claire; Nielsen, Karen; Milette, Katherine; Pope, Janet; Frech, Tracy; Gholizadeh, Shadi; Hummers, Laura; Johnson, Sindhu R; Piotrowski, Pamela; Jewett, Lisa; Gordon, Jessica; Chung, Lorinda; Bilsker, Dan; Turner, Kimberly A; Cumin, Julie; Welling, Joep; Fortune, Catherine; Leite, Catarina; Gottesman, Karen; Sauve, Maureen; Rodríguez-Reyna, Tatiana S; Hudson, Marie; Larche, Maggie; van Breda, Ward; Suarez-Almazor, Maria E; Bartlett, Susan J; Malcarne, Vanessa L; Mayes, Maureen D; Boutron, Isabelle; Mouthon, Luc; Wigley, Fredrick; Thombs, Brett D.
Afiliação
  • Carrier ME; Lady Davis Institute of the Jewish General Hospital, Montreal, QC, Canada.
  • Kwakkenbos L; Behavioural Science Institute, Clinical Psychology, Radboud University, Nijmegen, Netherlands.
  • Nielson WR; St Joseph's Health Care, London, ON, Canada.
  • Fedoruk C; Lady Davis Institute of the Jewish General Hospital, Montreal, QC, Canada.
  • Nielsen K; Scleroderma Society of Ontario, Hamilton, ON, Canada.
  • Milette K; Lady Davis Institute of the Jewish General Hospital, Montreal, QC, Canada.
  • Pope J; University of Western Ontario, London, ON, Canada.
  • Frech T; University of Utah, Salt Lake City, UT, United States.
  • Gholizadeh S; California School of Professional Psychology/Alliant, Los Angeles, CA, United States.
  • Hummers L; Johns Hopkins University School of Medicine, Baltimore, MD, United States.
  • Johnson SR; Toronto Scleroderma Program, Mount Sinai Hospital & Toronto Western Hospital, Toronto, ON, Canada.
  • Piotrowski P; Division of Neurosurgery, Department of Surgery, University of Toronto, Toronto, ON, Canada.
  • Jewett L; Private practice - Nutrition, Hamilton, ON, Canada.
  • Gordon J; Lady Davis Institute of the Jewish General Hospital, Montreal, QC, Canada.
  • Chung L; Hospital for Special Surgery, New York, NY, United States.
  • Bilsker D; Departments of Pediatrics, Biomedical Data Science, Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, United States.
  • Turner KA; Simon Fraser University, Burnaby, BC, Canada.
  • Cumin J; University of British Columbia, Vancouver, BC, Canada.
  • Welling J; Lady Davis Institute of the Jewish General Hospital, Montreal, QC, Canada.
  • Fortune C; Lady Davis Institute of the Jewish General Hospital, Montreal, QC, Canada.
  • Leite C; NVLE Dutch patient organization for systemic autoimmune diseases, Utrecht, Netherlands.
  • Gottesman K; Scleroderma Society of Ontario, Hamilton, ON, Canada.
  • Sauve M; University of Minho, Braga, Portugal.
  • Rodríguez-Reyna TS; Scleroderma Foundation, Los Angeles, CA, United States.
  • Hudson M; Scleroderma Society of Ontario, Hamilton, ON, Canada.
  • Larche M; Scleroderma Canada, Hamilton, ON, Canada.
  • van Breda W; Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
  • Suarez-Almazor ME; Lady Davis Institute of the Jewish General Hospital, Montreal, QC, Canada.
  • Bartlett SJ; Department of Medicine, McGill University, Montreal, QC, Canada.
  • Malcarne VL; McMaster University, Hamilton, ON, Canada.
  • Mayes MD; Faculty of Behavioural and Movement Sciences, Vrije University, Amsterdam, Netherlands.
  • Boutron I; University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Mouthon L; Department of Medicine, McGill University, Montreal, QC, Canada.
  • Wigley F; San Diego State University, San Diego, CA, United States.
  • Thombs BD; University of Texas McGovern School of Medicine, Houston, TX, United States.
JMIR Res Protoc ; 9(4): e16799, 2020 04 24.
Article em En | MEDLINE | ID: mdl-32329747
ABSTRACT

BACKGROUND:

Systemic sclerosis (SSc), or scleroderma, is a rare disease that often results in significant disruptions to activities of daily living and can negatively affect physical and psychological well-being. Because there is no known cure, SSc treatment focuses on reducing symptoms and disability and improving health-related quality of life (HRQoL). Self-management programs are known to increase self-efficacy for disease management in many chronic diseases. The Scleroderma Patient-centered Intervention Network (SPIN) developed a Web-based self-management program (SPIN self-management; SPIN-SELF) to increase self-efficacy for disease management and to improve HRQoL for patients with SSc.

OBJECTIVE:

The proposed study aims to assess the feasibility of conducting a full-scale randomized controlled trial (RCT) of the SPIN-SELF program by evaluating the trial implementation processes, required resources and management, scientific aspects, and participant acceptability and usage of the SPIN-SELF program.

METHODS:

The SPIN-SELF feasibility trial will be conducted via the SPIN Cohort. The SPIN Cohort was developed as a framework for embedded pragmatic trials using the cohort multiple RCT design. In total, 40 English-speaking SPIN Cohort participants with low disease management self-efficacy (Self-Efficacy for Managing Chronic Disease Scale score ≤7), who have indicated interest in using a Web-based self-management program, will be randomized with a 32 ratio into the SPIN-SELF program or usual care for 3 months. Feasibility outcomes include trial implementation processes, required resources and management, scientific aspects, and patient acceptability and usage of the SPIN-SELF program.

RESULTS:

Enrollment of the 40 participants occurred between July 5, 2019, and July 27, 2019. By November 25, 2019, data collection of trial outcomes was completed. Data analysis is underway, and results are expected to be published in 2020.

CONCLUSIONS:

The SPIN-SELF program is a self-help tool that may improve disease-management self-efficacy and improve HRQoL in patients with SSc. The SPIN-SELF feasibility trial will ensure that trial methodology is robust, feasible, and consistent with trial participant expectations. The results will guide adjustments that need to be implemented before undertaking a full-scale RCT of the SPIN-SELF program. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID) DERR1-10.2196/16799.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Prognostic_studies Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Prognostic_studies Idioma: En Ano de publicação: 2020 Tipo de documento: Article